

SPECTRUM PHARMACEUTICALS INC

Form 8-K

August 20, 2003

Table of Contents

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

**PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES AND EXCHANGE ACT OF 1934**

August 20, 2003 (August 18, 2003)
Date of Report (Date of earliest event reported)

SPECTRUM PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware	000-28782	93-0979187
(State or other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification Number)
157 Technology Drive Irvine, California		92618
(Address of principal executive offices)		(Zip Code)
	(949) 788-6700	
	(Registrant's telephone number, including area code)	
	N/A	
	(Former Name or Former Address, if Changed Since Last Report)	

TABLE OF CONTENTS

Item 5. Other Events

Item 7. Exhibits

SIGNATURES

EXHIBIT INDEX

EXHIBIT 99.1

Table of Contents

Item 5. Other Events

On August 18, 2003, Spectrum Pharmaceuticals, Inc. (the Company) and Lannett Company, Inc. announced that they have entered into an exclusive supply, marketing and distribution agreement for ciprofloxacin.

A copy of the Company's press release is attached hereto as Exhibit 99.1 and is incorporated herein by this reference.

Item 7. Exhibits

Exhibits:

99.1 Press release dated August 18, 2003.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SPECTRUM PHARMACEUTICALS, INC.

Date: August 20, 2003

By: /s/ Rajesh C. Shrotriya

Name: Rajesh C. Shrotriya, M.D.

Title: Chairman, Chief Executive Officer and President

Table of Contents

EXHIBIT INDEX

Exhibits:

99.1 Press release dated August 18, 2003.